ART MEDICAL Ltd. is pleased to announce its collaboration with Teva Israel. Under the terms of the agreement, Teva Israel will market and distribute ART MEDICAL's ground-breaking smART+ Platform in Israel's intensive care units.
NETANYA, ISRAEL / ACCESSWIRE / March 16, 2023 / The smART+ Platform is a robotic-assisted technology that aims to reduce complications related to feeding tube malposition, malnutrition, Ventilator-Associated Pneumonia (VAP), and Acute Kidney Injury (AKI). By delivering transformative new-to-the-world data, the smART+ Platform enables medical staff to take a comprehensive approach to critical care, make informed decisions and improve patient outcomes.
Current related practices in intensive care units rely mostly on manual work and cumbersome procedures. ICU patients are routinely subjected to the risks of malnutrition, tube malposition, and pneumonia. Without technological solutions, nutrition treatment leads to inaccuracies, increased workloads on care teams, and generic nutrition plans that are neither personalized nor updated in real time. The smART+ Platform uses a proprietary sensor-based feeding tube, continuous metabolic assessment, and algorithms, to provide real-time monitoring and closed-loop feedback, resulting in better and personalized care for critically ill patients.
ART MEDICAL's Founder and CEO, Liron Elia, says, "Our goal, at ART MEDICAL, is to improve patient outcomes through cutting-edge technology. By integrating real-time data, monitoring, and control mechanisms, the smART+ Platform addresses several of the greatest clinical challenges of intensive care units. This powerful combination provides a comprehensive and innovative nutritional therapy practice as well as optimized care delivery. We are thrilled to partner with Teva Israel to bring our technology to critically ill patients and clinical teams in ICUs."
Yossi Ofek, GM-Teva Israel, SVP; Cluster Head - Middle East, Africa & Ukraine says:
"Teva Israel continually strives to offer innovative and safe treatment options - both in the community and in hospitals - in order to improve the lives and health of patients.
"The innovative development of an Israeli company, ART MEDICAL, is intended to ensure that patients in intensive care units receive the most advanced treatment offered today that can minimize complications related to hospitalization and reduce length of stay."
About Teva Israel:
'Teva Israel' is the home-based marketing arm of Teva Pharmaceutical Industries Ltd, where it has been working to improve the lives and health of patients, for over 120 years, through high-quality and affordable medicines.
As a leading player in the local health market and particularly in the generics and OTC markets, Teva Israel provides unique services in Israel to Israeli residents, through its logistics company SLE - and markets a wide variety of medicines and products: from original innovative medicines and generic medicines, through medical equipment and devices for hospitals, to over the counter (OTC) medicines and baby milk formula.
Teva Israel is also an innovation incubator for Teva Global and established, in collaboration with Philips, Sanara Ventures, a platform for investments in start-up companies in the fields of digital medicine and medical devices. In Israel, one of every four prescriptions is for a Teva drug, while the annual savings that the company's generic drugs bring to the Israeli healthcare system is estimated at about one and a half billion shekels, per year.
About ART MEDICAL
ART MEDICAL is on a mission to save lives through technological innovations and redefine the future of critical care. Our goal is to see ICU patients get better faster with the help of real-time nutrition management. Visit www.artmedical.com or follow us on LinkedIn for more information.
Forward-Looking Statements of ART MEDICAL
ART MEDICAL developed the smART+™ Platform as a holistic approach for the next-generation ICU, featuring an ecosystem of sensor-based tools, software, and algorithms. smART+ is designed to prevent ICU-acquired complications. The smART+ Platform aims to reduce length of ventilation days and length of stay that are attributed to malnutrition, VAP, and other secondary infections and complications, ultimately providing better care, and dramatically reducing healthcare costs.
THIS PRESS RELEASE AND ITS CONTENT IS NOT INTENDED AS AN OFFERING OR AS A SOLICITATION TO AN OFFERING TO PURCHASE SECURITIES OF ANY OF THE ABOVE-MENTIONED COMPANIES OR ANY OF THEIR AFFILIATES, DIRECTLY OR INDIRECTLY, AND YOU MAY NOT RELY ON THIS PRESS RELEASE IN CONNECTION WITH AN INVESTMENT DECISION.
SVP Business Development
SOURCE: ART MEDICAL